Significantly improved delivery of functional proteins to the brain demonstrated in vivo
Exosomes have potential to transform effective drug delivery for key neurological diseases
11 October 2021: ReNeuron Group plc (AIM: RENE), a global leader in the development of exosome therapeutics, announces positive data that provides clear pre-clinical proof-of-concept that ReNeuron’s novel exosome drug delivery technology can effectively deliver therapeutic proteins to the specific region of the brain affected by several neurological diseases.